Archive

Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference...

Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its...

Azenta, Inc. (Nasdaq: AZTA) announced that Lawrence Y. Lin, Executive Vice President and Chief Financial Officer, will participate in the Virtual KeyBanc Capital Markets Healthcare Forum on...

Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in...

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical...

Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a...

Azenta, Inc. (Nasdaq: AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of...

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation...

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA...

Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company...